{
    "2019-08-27": [
        [
            {
                "time": "",
                "original_text": "健帆生物(300529.SZ)发布半年报 净利润升45.63%至3.06亿元",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "半年报",
                        "净利润",
                        "增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物：上半年净利润同比增45.63%",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "上半年",
                        "净利润",
                        "同比增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物：节余募集资金永久性补充流动资金",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "募集资金",
                        "补充流动资金"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "【广证恒生医药】-健帆生物（300529）-点评报告-灌流器在肾病和肝病领域加速渗透，2019年H1扣非后业绩54%高增长",
                "features": {
                    "keywords": [
                        "广证恒生医药",
                        "健帆生物",
                        "灌流器",
                        "肾病",
                        "肝病",
                        "高增长"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}